Skip to main content

Advertisement

SpringerLink
Log in

Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

One of the most recent of tumor molecular characterization approaches is the microRNA (miR) expression profile. No single marker is sufficiently accurate for clinical use. Numerous biomarkers panels were created for three main purposes: tumor subtype, classification and, early detection, and prediction of tumor responses to treatment and prognosis of patients. miR-21-5p and miR-126-3p have received special attention because of their relationship with many cancer sites such as lung cancer, colorectal cancer, and renal cell carcinoma. We aimed to study their diagnostic and prognostic utility in lung cancer patients. Serum carcinoembryonic antigen (CEA) level was measured using an enzyme-linked immunosorbent assay (ELISA) technique. The expression levels of miR-21-5p and miR-126-3p were determined by real-time PCR in 60 non small cell lung cancer (NSCLC) patients and 40 healthy controls to detect diagnostic utility. Moreover, it was correlated with all disease clinicopathological characters and patient survival. Higher miR-21-5p and lower miR-126-3p levels were found in lung cancer patients than in controls. The sensitivity of CEA and miR-21-5p and miR-126-3p were 78.3, 96.7, and 90% at cutoff points 7.5, 2.35, and 2.175, respectively to distinguish NSCLC patients from controls. On combining both miR-21-5p and miR-126-3p, an improvement of sensitivity to 97% was noted. For patients, miR-21-5P increased significantly with metastatic stage and the highest grade (GIII). There was significantly longer overall survival (OS) among patients with early stages, lower grades GI&II, low miR-21-5p, and high miR-126-3p. miR-126-3p and presence of metastasis, the last two factors were the independent factors affecting OS with a hazard ratio of 0.26 (95% CI: 0.06–1.09) and 3.64 (95% CI: 1.22–16.5), respectively. Circulating miR-21-5p and miR-126-3p may play a significant role in diagnosis and prognosis in NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. WHO (2018) Cancer, key facts. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed 11 Jan 2021

  2. American cancer Society (2019) What is lung cancer? https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Retrieved 11 Jan 2021

  3. Liao Y, Cheng S, Xiang J, Luo C (2018) lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients. Eur Rev Med Pharmacol Sci 22:1686–1692. https://doi.org/10.26355/eurrev_201803_1458

    Article  CAS  PubMed  Google Scholar 

  4. Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T et al (2008) Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med 168:1541–1549. https://doi.org/10.1001/archinte.168.14.1541

    Article  PubMed  Google Scholar 

  5. Ye X, Weinberg RA (2015) Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol 25(11):675–686. https://doi.org/10.1016/j.tcb.2015.07.012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis, and treatment selection. Nat Rev Cancer 5:845–856. https://doi.org/10.1038/nrc1739

    Article  CAS  PubMed  Google Scholar 

  7. Felekkis K, Touvana E, Stefanou C, Deltas C (2010) MicroRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 14(4):236–240 (PMID: 21311629)

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Ahmad J, Hasnain SE, Siddiqui MA, Ahamed M, Musarrat J, Al-Khedhairy AA (2013) MicroRNA in carcinogenesis & cancer diagnostics: a new paradigm. Indian J Med Res 137(4):680–694 (PMID: 23703335)

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Makarem N, Mourad A, Nassar FJ, Nasr R (2016) Circulating microRNAs: potential biomarkers in cancer detection, diagnosis and prognosis. J Med Liban 64(2):116–122 (PMID: 30452151)

    PubMed  Google Scholar 

  10. Takahashi RU, Prieto-Vila M, Kohama I, Ochiya T (2018) MicroRNA in body fluids: development of the novel plat form for cancer therapeutics and diagnosis. Gan To Kagaku Ryoho 45(6):899–905 (PMID: 30026410)

    CAS  PubMed  Google Scholar 

  11. Mengying C, Hongdan W, Xiaoxiao Y, Dan Z, Yingjun X, Ranji C, Xuewen Z (2019) Circulating MicroRNAs in cancer: potential and challenge. Front Genet 10:626. https://doi.org/10.3389/fgene.2019.00626

    Article  CAS  Google Scholar 

  12. Park SK, Park YS, Ahn JY et al (2016) MiR 21–5p as a predictor of recurrence in young gastric cancer patients. J Gastroenterol Hepatol 31(8):1429–1435. https://doi.org/10.1111/jgh.13300

    Article  CAS  PubMed  Google Scholar 

  13. Li X, Wu X (2018) MiR-21-5p promotes the progression of non-small-cell lung cancer by regulating the expression of SMAD7. Onco Targets Ther 11:8445–8454. https://doi.org/10.2147/OTT.S172393

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Liu R, Zhang Y, Zhang S, Cheng Z, Yu J, Zhou S, Song J (2019) MiR-126–3p suppresses the growth, migration and invasion of NSCLC via targeting CCR1. Eur Rev Med Pharmacol Sci 23:679–689. https://doi.org/10.26355/eurrev_201901_16881

    Article  CAS  PubMed  Google Scholar 

  15. Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H, Liu X, Le H, Zhang Y (2016) Diagnostic value of serum miR-182, miR-183, miR-210 and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS ONE 11(4):e0153046. https://doi.org/10.1371/journal.pone.0153046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Grimolizzi F, Monaco F, Leoni F, Bracci M, Stafolani S, Bersaglieri C et al (2017) Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression. Sci Rep 7:15277. https://doi.org/10.1038/s41598-017-15475-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Oken M, Creech R, Tormey D et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655 (PMID: 7165009)

    Article  CAS  Google Scholar 

  18. Amin M, Greene F, Edge S, Compton C, Gershenwald J, Brookl R, et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more ʻʻpersonalizedʼʼ approach to cancer staging. CA Cancer J Clin 67:93–99. Doi: https://doi.org/10.3322/caac.21388

  19. Ettinger D, Wood D, Aisner D, Akerley W et al (2017) Non-small cell lung cancer, Version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15(4):504–535. https://doi.org/10.6004/jnccn.2017.0050

    Article  PubMed  Google Scholar 

  20. Bade B, Cruz C (2020) Lung cancer 2020. Epidemiology, etiology, and prevention. Clin Chest Med 41(1):1–24. https://doi.org/10.1016/j.ccm.2019.10.001

    Article  PubMed  Google Scholar 

  21. Zhang S, Liu Z (2016) Effect of miRNAs in lung cancer suppression and oncogenesis. Open Life Sci 11:441–446. https://doi.org/10.1515/biol-2016-0058

    Article  CAS  Google Scholar 

  22. Li X, Wu X (2018) MiR-21–5p promotes the progression of non-small-cell lung cancer by regulating the expression of SMAD7. OncoTargets Ther 11:8445–8454. https://doi.org/10.2147/OTT.S172393

    Article  CAS  Google Scholar 

  23. Shi J, Zhu J (2016) Health resource utilization in patients with advanced non-small cell lung cancer receiving chemotherapy in China. Clin Drug Investig 36(1):77–86. https://doi.org/10.1007/s40261-015-0356-9

    Article  CAS  PubMed  Google Scholar 

  24. Ergün S, Ulasli M, Igci YZ, Sevil K et al (2015) The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. Mol Biol Rep. https://doi.org/10.1007/s11033-014-3793-2

    Article  PubMed  Google Scholar 

  25. Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39(16):7223–7233. https://doi.org/10.1093/nar/gkr254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kunz M, Göttlich C, Walles T, Nietzer S, Dandekar G, Dandekar T (2017) MicroRNA-21 versus microRNA-34: lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. Tumor Biol 39(7):1010428317706430. https://doi.org/10.1177/1010428317706430

    Article  CAS  Google Scholar 

  27. Iqbala MA, Aroraa S, Prakasam G, Calinc GA, Syed MA (2019) MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med 70(2019):3–20. https://doi.org/10.1016/j.mam.2018.07.003

    Article  CAS  Google Scholar 

  28. Zheng W, Zhou Y, Lu J, Xu H, Lei L, Chen C, Zhao J, Xu L (2017) The prognostic value of miR-126 expression in non-small-cell lung cancer: a meta-analysis. Cancer Cell Int 17:71. https://doi.org/10.1186/s12935-017-0440-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Wang ZX, Bian HB, Wang JR, Cheng ZX et al (2011) Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol 104:847–851. https://doi.org/10.1002/jso.22008

    Article  CAS  PubMed  Google Scholar 

  30. Võsa U, Vooder T, Kolde R, Jaak Vilo J, Metspalu A, Annilo T (2013) Meta-analysis of microRNA expression in lung cancer. Int J Cancer 132:2884–2893. https://doi.org/10.1002/ijc.27981

    Article  CAS  PubMed  Google Scholar 

  31. Sun L, Zhou H, Yang Y, Chen J et al (2020) Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer. Biosci Rep 40(5):9. https://doi.org/10.1042/BSR20200349

    Article  Google Scholar 

  32. Vergho D, Kneitz S, Rosenwald A, Scherer C et al (2018) Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. Oncol Lett 16:2777–2782. https://doi.org/10.1186/1471-2407-14-25

    Article  Google Scholar 

  33. Donnem T, Fenton G, Lonvik K, Berg T, Eklo K, Andersen S, Stenvold H, Al-Shibli K, Al-Saad S, Bremne RM et al (2012) MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS ONE 7(1):29671. https://doi.org/10.1371/journal.pone.0029671

    Article  CAS  Google Scholar 

  34. Xu X, Zhu S, Tao Z, Ye S (2018) High circulating miR-18a, miR-20a, and miR-92a expression correlates with poor prognosis in patients with non-small cell lung cancer. Cancer Med 7:21–31. https://doi.org/10.1002/cam4.1238

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

There was no funding for this study.

Author information

Authors and Affiliations

  1. Faculty of Medicine, Medical Biochemistry and Molecular Biology Department, Menoufia University, Shebin elKom, Menoufia, 32511, Egypt

    Shimaa El-Shafey Soliman

  2. Medical Biochemistry Unit, Department of Pathology, College of Medicine, Qassim University, Buraydah, Saudi Arabia

    Shimaa El-Shafey Soliman

  3. Faculty of Science, Chemistry Department, Menoufia University, Menoufia, Egypt

    A. H. Abdelaleem

  4. Faculty of Medicine, Department of Clinical Oncology and Nuclear Medicine, Menoufia University, Menoufia, Egypt

    Alshimaa Mahmoud Alhanafy

  5. Department of Public Health and Community Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt

    Reda Abdel Latif Ibrahem

  6. Chemist at Faculty of Science, Menoufia University, Menoufia, Egypt

    Asmaa S. Abo Elhaded

  7. Biochemistry Division of Chemistry Department, Faculty of Science, Menoufia University, Menoufia, Egypt

    Mohamed F. A. Assar

Authors
  1. Shimaa El-Shafey Soliman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. H. Abdelaleem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alshimaa Mahmoud Alhanafy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reda Abdel Latif Ibrahem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Asmaa S. Abo Elhaded
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohamed F. A. Assar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shimaa El-Shafey Soliman.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

Consent was given by all participants and was approved by the Ethical Committee of Medical Research, Faculty of Medicine, Menoufia University.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 411 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soliman, S.ES., Abdelaleem, A.H., Alhanafy, A.M. et al. Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer. Mol Biol Rep 48, 2543–2552 (2021). https://doi.org/10.1007/s11033-021-06302-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-021-06302-3

Keywords

Search

Navigation